Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

NCT03274661 PHASE2 COMPLETED Results posted

Phase II trial in which patients with metastatic solid tumors experiencing progression after first line standard chemotherapy or for which there is no standard chemotherapy, and for which pembrolizumab does not have an FDA or compendia listing approved indication, will receive pembrolizumab intravenously at a dose of 200 mg every 3 weeks.

Details

Lead sponsor	Baptist Health South Florida
Phase	PHASE2
Status	COMPLETED
Enrolment	52
Start date	Fri Nov 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Mar 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Solid Tumor, Adult

Interventions

• Pembrolizumab 200 mg Q3W

Countries

United States